{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:34:08Z","timestamp":1789385648621,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science and Technology Council in Taiwan","award":["grant NSTC 112-2628-B-006-008-MY3"],"award-info":[{"award-number":["grant NSTC 112-2628-B-006-008-MY3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      It is unclear whether the time-varying mediation effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the three-point major adverse cardiovascular event (3P-MACE) outcomes, including nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death, via HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , urine albumin-to-creatinine ratio (UACR), and systolic blood pressure (SBP) vary by types of GLP-1RAs, and patient subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A causal mediation analysis was applied to assess the mediation effects of HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , UACR, and SBP on the 3P-MACE with liraglutide and semaglutide over time, using the LEADER and SUSTAIN-6 trials. We further explored the heterogeneity in mediation effects in subsets of vulnerable patients, including those with an estimated glomerular filtration rate (eGFR) level of &lt;\u200960\u00a0ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      or established cardiovascular diseases (CVDs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Individual-level data consisting of 9340 (liraglutide: 4668; placebo: 4672) and 3297 (semaglutide: 1648; placebo: 1649) subjects from the LEADER and SUSTAIN-6 trials, respectively, was utilized for this study. The study population aged around 64.2\u201364.4\/64.4\u201364.8 years old, with 64.0%\u201364.5%\/58.5%\u201363.0% of males, and having a diabetes duration of 12.8\u201312.9\/13.2\u201314.3 years in the LEADER\/SUSTAIN-6 trials, respectively. Among study populations, those established CVDs (e.g., heart failure, stroke, myocardial infarction) accounted for 14.0%\u201335.4% in the LEADER trial, whereas 13.7%\u201361.9% in the SUSTAIN-6 trial. At the end of each trial, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      contributed the most to liraglutide\u2019s\/semaglutide\u2019s effect on 3P-MACE (38.2%, 95% confidence interval: 13.8%\u2013194.5%\/51.8%, 29.6%\u201386.7%), followed by UACR (17.9%, 8.5%\u201361.9%\/12.4%, 6.1%\u201332.4%) and SBP (6.8%, 2.2%\u201331.0%\/6.7%, 2.9%\u201311.7%), respectively. Over the trial period, the effect of liraglutide mediated by HbA\n                      <jats:sub>1c<\/jats:sub>\n                      increased from 31.3% to 38.2%, whereas the effects of semaglutide mediated by HbA\n                      <jats:sub>1c<\/jats:sub>\n                      remained stable from 52.5% to 51.8%. For patients with eGFR\u2009&lt;\u200960\u00a0ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , HbA\n                      <jats:sub>1c<\/jats:sub>\n                      was the leading mediator (35.2%) of semaglutide-associated 3P-MACE, while the mediation effects via HbA\n                      <jats:sub>1c<\/jats:sub>\n                      (7.2%), UACR (11.8%), and SBP (5.1%) on liraglutide-associated 3P-MACE seemed similar and smaller. For patients with established CVDs, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      was the leading mediator of liraglutide- (25.3%) and semaglutide-associated 3P-MACE (51.2%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The HbA\n                      <jats:sub>1c<\/jats:sub>\n                      -mediated effects of liraglutide and semaglutide varied over time and across patient subgroups. HbA\n                      <jats:sub>1c<\/jats:sub>\n                      consistently explained a larger proportion of mediation compared to UACR and SBP, with patterns suggesting that mediation through HbA\n                      <jats:sub>1c<\/jats:sub>\n                      may differ by underlying risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-025-03007-w","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T05:23:55Z","timestamp":1763961835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials"],"prefix":"10.1186","volume":"24","author":[{"given":"Zi-Yang","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Tz","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihchen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"7","key":"3007_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2337\/dc19-2251","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Pratley RE, Linder M, Monk Fries T, \u00d8rsted DD, Zinman B. LEADER trial Investigators. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care. 2020;43(7):1546\u201352. https:\/\/doi.org\/10.2337\/dc19-2251.","journal-title":"Diabetes Care"},{"issue":"1","key":"3007_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12933-021-01386-4","volume":"20","author":"M Konig","year":"2021","unstructured":"Konig M, Riddle MC, Colhoun HM, Branch KR, Atisso CM, Lakshmanan MC, Mody R, Raha S, Gerstein HC. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovasc Diabetol. 2021;20(1):194. https:\/\/doi.org\/10.1186\/s12933-021-01386-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3007_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/cvr\/cvae237","volume":"121","author":"ZY Peng","year":"2025","unstructured":"Peng ZY, Lee YH, Ou HT, Kuo S. Temporal changes in mediation effects on cardiovascular and microvascular outcomes with glucagon-like peptide-1 receptor agonist therapy: a post-hoc analysis of the LEADER trial. Cardiovasc Res. 2025;121(1):10\u20132. https:\/\/doi.org\/10.1093\/cvr\/cvae237.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"3007_CR4","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.14443","volume":"23","author":"JFE Mann","year":"2021","unstructured":"Mann JFE, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, Vilsb\u00f8ll T, Wolthers B, Perkovic V. Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis. Diabetes Obes Metab. 2021;23(9):2058\u201366. https:\/\/doi.org\/10.1111\/dom.14443.","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement_1","key":"3007_CR5","doi-asserted-by":"publisher","first-page":"ehae666.2792","DOI":"10.1093\/eurheartj\/ehae666.2792","volume":"45","author":"H Colhoun","year":"2024","unstructured":"Colhoun H, Lincoff AM, Linder M, Hardt-Lindberg S, Hovingh GK, Kahn S, Kalayci Oral T, Lingvay I, Plutzky J, Ryan DH, Weeke PE, Deanfield J, The SELECT investigator group. Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial. Eur Heart J. 2024;45(Supplement_1), ehae666.2792, https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.2792.","journal-title":"Eur Heart J"},{"issue":"4","key":"3007_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"3007_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"3","key":"3007_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/bimj.201800263","volume":"62","author":"OO Aalen","year":"2020","unstructured":"Aalen OO, Stensrud MJ, Didelez V, Daniel R, R\u00f8ysland K, Strohmaier S. Time-dependent mediators in survival analysis: modeling direct and indirect effects with the additive hazards model. Biom J. 2020;62(3):532\u201349. https:\/\/doi.org\/10.1002\/bimj.201800263.","journal-title":"Biom J"},{"issue":"1 Suppl 1","key":"3007_CR9","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181\u2013206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"3007_CR10","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S207\u201338. https:\/\/doi.org\/10.2337\/dc25-S010","journal-title":"Diabetes Care"},{"key":"3007_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. https:\/\/doi.org\/10.3389\/fendo.2019.00155.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3007_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Verg\u00e8s B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0\u00a0mg vs once-daily liraglutide 1.2\u00a0mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100\u20139. https:\/\/doi.org\/10.1016\/j.diabet.2019.101117.","journal-title":"Diabetes Metab"},{"issue":"1","key":"3007_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ajkd.2023.12.018","volume":"84","author":"N Rasaratnam","year":"2024","unstructured":"Rasaratnam N, Salim A, Blackberry I, Cooper ME, Magliano DJ, van Wijngaarden P, Varadarajan S, Sacre JW, Shaw JE. Urine albumin-creatinine ratio variability in people with type 2 diabetes: clinical and research implications. Am J Kidney Dis. 2024;84(1):8\u2013e171. https:\/\/doi.org\/10.1053\/j.ajkd.2023.12.018.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"3007_CR14","doi-asserted-by":"publisher","first-page":"e002276","DOI":"10.1161\/JAHA.115.002276","volume":"4","author":"ST Hardy","year":"2015","unstructured":"Hardy ST, Loehr LR, Butler KR, Chakladar S, Chang PP, Folsom AR, Heiss G, MacLehose RF, Matsushita K, Avery CL. Reducing the blood pressure-related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control. J Am Heart Assoc. 2015;4(10):e002276. https:\/\/doi.org\/10.1161\/JAHA.115.002276.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"3007_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x","volume":"68","author":"LV Jacobsen","year":"2009","unstructured":"Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68(6):898\u2013905. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03536.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3007_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2215\/CJN.10380917","volume":"13","author":"RJ MacIsaac","year":"2018","unstructured":"MacIsaac RJ, Thomas MC. Effects of diabetes medications targeting the incretin system on the kidney. Clin J Am Soc Nephrol. 2018;13(2):321\u20133. https:\/\/doi.org\/10.2215\/CJN.10380917.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3007_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2215\/CJN.01260120","volume":"15","author":"DZ Cherney","year":"2020","unstructured":"Cherney DZ, Tuttle KR. Liraglutide for the treatment of type 2 diabetes and safety in diabetic kidney disease: liraglutide and diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(4):444\u20136. https:\/\/doi.org\/10.2215\/CJN.01260120.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"3007_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/ckj\/sfac069","volume":"15","author":"A Granata","year":"2022","unstructured":"Granata A, Maccarrone R, Anzaldi M, Leonardi G, Pesce F, Amico F, Gesualdo L, Corrao S. GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the Art. Clin Kidney J. 2022;15(9):1657\u201365. https:\/\/doi.org\/10.1093\/ckj\/sfac069.","journal-title":"Clin Kidney J"},{"issue":"7","key":"3007_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374. https:\/\/doi.org\/10.1038\/s41569-023-00849-3.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"3007_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, Joles JA, van Raalte DH. GLP-1 and the kidney: from physiology to Pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605\u201328. https:\/\/doi.org\/10.1038\/nrneph.2017.123.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"3007_CR21","doi-asserted-by":"publisher","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","volume":"301","author":"RO Crajoinas","year":"2011","unstructured":"Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G, Girardi AC. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Ren Physiol. 2011;301(2):F355\u201363. https:\/\/doi.org\/10.1152\/ajprenal.00729.2010.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"9","key":"3007_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/dom.14776","volume":"24","author":"D Yuan","year":"2022","unstructured":"Yuan D, Sharma H, Krishnan A, Vangaveti VN, Malabu UH. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2022;24(9):1869\u201381. https:\/\/doi.org\/10.1111\/dom.14776.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3007_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201337. https:\/\/doi.org\/10.1016\/j.diabres.2015.07.015.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"3007_CR24","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2337\/dc20-2715","volume":"44","author":"N Stempniewicz","year":"2021","unstructured":"Stempniewicz N, Vassalotti JA, Cuddeback JK, Ciemins E, Storfer-Isser A, Sang Y, Matsushita K, Ballew SH, Chang AR, Levey AS, Bailey RA, Fishman J, Coresh J. Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. Health care organizations. Diabetes Care. 2021;44(9):2000\u20139. https:\/\/doi.org\/10.2337\/dc20-2715.","journal-title":"Diabetes Care"},{"issue":"7","key":"3007_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/a-0581-4870","volume":"127","author":"K Kostev","year":"2019","unstructured":"Kostev K, Lucas A, Jacob L. Frequency of blood pressure and estimated glomerular filtration rate testing in type 2 diabetes mellitus: a retrospective study with 43,509 patients. Exp Clin Endocrinol Diabetes. 2019;127(7):455\u201360. https:\/\/doi.org\/10.1055\/a-0581-4870.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"3007_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/ACI.0b013e3283609831","volume":"13","author":"D Curran-Everett","year":"2013","unstructured":"Curran-Everett D, Milgrom H. Post-hoc data analysis: benefits and limitations. Curr Opin Allergy Clin Immunol. 2013;13(3):223\u20134. https:\/\/doi.org\/10.1097\/ACI.0b013e3283609831.","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03007-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:35:23Z","timestamp":1767054923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3007"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03007-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To comply with the Declaration of Helsinki, both trials adhered to the policy of the institutional review board or ethics committee at the corresponding study site, with written informed consent provided to the trial participants at enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"465"}}